Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Geese

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
European Journal of Biochemistry|March 26, 2003
In vitro analysis of the relationship between endonuclease and maturase activities in the bi-functional group I intron-encoded protein, I-AniIWilliam J Geese, Yong K Kwon, Xiaoping Wen, et al.
AIDS (London, England)|August 2, 2008
Genetic analysis implicates resistin in HIV lipodystrophyKoustubh Ranade, William J Geese, Mustafa Noor, et al.
Molecular Diagnosis & Therapy|June 29, 2019
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung CancerHan Chang, Ariella Sasson, Sujaya Srinivasan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004George Somlo, Francesco Atzori, Lewis C Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2025
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized TrialAndrew J Armstrong, Hilary Dietz, David Balli, et al.
Pharmacogenetics and Genomics|September 17, 2008
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonistsWilliam J Geese, William Achanzar, Cindy Rubin, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2018
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 StudyScott Gettinger, Leora Horn, David Jackman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2023
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen PresentationCharles M Rudin, David Balli, W Victoria Lai, et al.
Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Biochemistry|March 26, 2003
In vitro analysis of the relationship between endonuclease and maturase activities in the bi-functional group I intron-encoded protein, I-AniIWilliam J Geese, Yong K Kwon, Xiaoping Wen, et al.
AIDS (London, England)|August 2, 2008
Genetic analysis implicates resistin in HIV lipodystrophyKoustubh Ranade, William J Geese, Mustafa Noor, et al.
Molecular Diagnosis & Therapy|June 29, 2019
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung CancerHan Chang, Ariella Sasson, Sujaya Srinivasan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004George Somlo, Francesco Atzori, Lewis C Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2025
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized TrialAndrew J Armstrong, Hilary Dietz, David Balli, et al.
Pharmacogenetics and Genomics|September 17, 2008
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonistsWilliam J Geese, William Achanzar, Cindy Rubin, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2018
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 StudyScott Gettinger, Leora Horn, David Jackman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2023
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen PresentationCharles M Rudin, David Balli, W Victoria Lai, et al.
Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Pageof 3